Fundraising FoxBioVentures — 2019 Investments
1 investments dated 2019 · listed companies and verified rows first · show all
Avirmaxavirmax.comin𝕏Nov 2019SEC filinghigh confidence
Avirmax is a preclinical-stage biopharmaceutical company developing AAV-based genetic medicines to treat chronic and degenerative ocular diseases.
BiotechDeep TechMedical DevicesHayward, US
Haifeng Chen(Director and Treasurer of the Issuer)inShengjiang Liu(Executive Officer, Director)
BoardNancy Chang(Director of the Issuer)
Board seatQianye Karen LiuYu Fang· per SEC Form D · $10M raise · filed Nov 2019
Co-investors3E Bioventures Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.